更新于：2024-12-17
Lansoprazole
兰索拉唑
更新于：2024-12-17
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C16H14F3N3O2S |
InChIKeyMJIHNNLFOKEZEW-UHFFFAOYSA-N |
CAS号103577-45-3 |
关联
201
项与 兰索拉唑 相关的临床试验Bioequivalence study of ?Lansoprazole 30 mg Capsule of Dorsa Pharmaceutical Co. and Agopton of Takeda as reference in 24 healthy male under fasting.
兰索拉唑肠溶胶囊在健康受试者中随机、开放、两制剂、两序列、单次给药、完全重复交叉设计空腹和餐后状态下生物等效性试验。
兰索拉唑肠溶胶囊在健康受试者中的单剂量、随机、开放、交叉、空腹和餐后人体生物等效性试验
100 项与 兰索拉唑 相关的临床结果
登录后查看更多信息
100 项与 兰索拉唑 相关的转化医学
登录后查看更多信息
100 项与 兰索拉唑 相关的专利（医药）
登录后查看更多信息
2,738
项与 兰索拉唑 相关的文献（医药）2024-12-31Emerging microbes & infections
Lansoprazole interferes with fungal respiration and acts synergistically with amphotericin B against multidrug-resistant
Candida auris
Article
作者: Li, Jianing ; Salama, Ehab A. ; Seleem, Mohamed N. ; Lanman, Nadia A. ; Utturkar, Sagar M. ; Meunier, Brigitte ; Hazbun, Tony R. ; Farhangian, Atena ; Wijeratne, Aruna ; Elgammal, Yehia
Candida auris has emerged as a problematic fungal pathogen associated with high morbidity and mortality. Amphotericin B (AmB) is the most effective antifungal used to treat invasive fungal candidiasis, with resistance rarely observed among clinical isolates. However, C. auris possesses extraordinary resistant profiles against all available antifungal drugs, including AmB. In our pursuit of potential solutions, we screened a panel of 727 FDA-approved drugs. We identified the proton pump inhibitor lansoprazole (LNP) as a potent enhancer of AmB's activity against C. auris. LNP also potentiates the antifungal activity of AmB against other medically important species of Candida and Cryptococcus. Our investigations into the mechanism of action unveiled that LNP metabolite(s) interact with a crucial target in the mitochondrial respiratory chain (complex III, known as cytochrome bc1). This interaction increases oxidative stress within fungal cells. Our results demonstrated the critical role of an active respiratory function in the antifungal activity of LNP. Most importantly, LNP restored the efficacy of AmB in an immunocompromised mouse model, resulting in a 1.7-log (∼98%) CFU reduction in the burden of C. auris in the kidneys. Our findings strongly advocate for a comprehensive evaluation of LNP as a cytochrome bc1 inhibitor for combating drug-resistant C. auris infections.
2024-12-31Emerging Microbes & Infections
Response to the letter to the editor: Lansoprazole interferes with fungal respiration and acts synergistically with amphotericin B against multidrug-resistant
Candida auris
*
Letter
作者: Li, Jianing ; Seleem, Mohamed N. ; Salama, Ehab A. ; Lanman, Nadia A. ; Utturkar, Sagar M. ; Meunier, Brigitte ; Hazbun, Tony R. ; Farhangian, Atena ; Wijeratne, Aruna ; Elgammal, Yehia
2024-12-31Emerging Microbes & Infections
Letter to the editor: lansoprazole interferes with fungal respiration and acts synergistically with amphotericin B against multidrug-resistant
Candida auris
Article
作者: Zhang, Yongsheng ; Zhu, Meng ; Pan, Fuzhen ; Wang, Hongyang
The study investigates the potential of lansoprazole, a proton pump inhibitor, to interfere with fungal respiration and enhance the antifungal activity of amphotericin B against multidrug-resistant Candida auris. The authors administered lansoprazole at concentrations significantly higher than typical therapeutic doses, which demonstrated promising results but also raised concerns about potential toxicity. We suggest incorporating a control group, monitoring toxicity indicators, performing pathological examinations, and conducting cellular assays to improve the study's rigor and reliability. We also highlight the need for further research into the mechanisms of lansoprazole's antifungal activity, its long-term effects on amphotericin B resistance, and potential drug-drug interactions with amphotericin B. Addressing these concerns is crucial for the clinical translation of lansoprazole as an adjuvant to amphotericin B.
181
项与 兰索拉唑 相关的新闻（医药）2024-12-17
·医药地理
医药出海核酸药物引进/卖出
2024-12-09
财报IPO申请上市
2024-12-08
·信狐药迅
疫苗信使RNA申请上市临床申请临床1期
100 项与 兰索拉唑 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 胃灼热 | 美国 | 2009-05-18 | |
| 慢性胃炎 | 澳大利亚 | 2009-01-14 | |
| 消化性溃疡 | 澳大利亚 | 2009-01-14 | |
| 应激性溃疡 | 日本 | 2006-10-20 | |
| 非糜烂性胃食管反流病 | 日本 | 2006-06-15 | |
| 食管炎 | 美国 | 2004-06-17 | |
| 反流性食管炎 | 日本 | 2000-12-12 | |
| 糜烂性食管炎 | 美国 | 1995-05-10 | |
| 良性胃溃疡 | 美国 | 1995-05-10 | |
| 胃食管反流 | 美国 | 1995-05-10 | |
| 吻合口溃疡 | 日本 | 1992-10-02 | |
| 十二指肠溃疡 | 日本 | 1992-10-02 | |
| 胃溃疡 | 日本 | 1992-10-02 | |
| Zollinger-Ellison综合征 | 日本 | 1992-10-02 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 幽门螺杆菌感染 | 临床3期 | 日本 | 2012-01-01 | |
| 胃肠道溃疡 | 临床3期 | 日本 | 2007-04-01 | |
| 骨关节炎 | 临床3期 | - | 2003-07-01 | |
| 溃疡 | 临床3期 | - | 2003-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 12 | 壓繭憲蓋壓蓋膚窪簾鏇(憲築簾淵願構簾餘願膚) = 壓網選鏇餘網築鏇構鏇 鑰鑰廠鏇艱淵蓋鑰夢夢 (鹽製製淵膚憲網選範願, 繭廠窪蓋遞壓鏇壓選艱 ~ 壓鹹齋淵積襯襯範糧願) 更多 | - | 2024-08-09 | |||
临床2期 | 248 | (X842 25 mg BID) | 積築積網艱鹽襯鹹餘願(觸憲壓壓繭範觸網糧淵) = 鑰鹹願鹹鬱繭衊糧鬱鏇 襯製繭膚衊糧齋憲顧窪 (網糧繭積壓願夢壓齋構, 鏇餘顧夢鑰餘製糧蓋膚 ~ 製鏇鹽築願憲構獵鏇築) 更多 | - | 2023-11-01 | ||
(X842 50 mg BID) | 積築積網艱鹽襯鹹餘願(觸憲壓壓繭範觸網糧淵) = 築遞壓夢醖鏇構夢簾廠 襯製繭膚衊糧齋憲顧窪 (網糧繭積壓願夢壓齋構, 艱製窪鹹顧餘糧願範鏇 ~ 築糧醖鹽網繭艱淵網醖) 更多 | ||||||
N/A | - | - | Vonoprazan 20mg once-daily | 憲窪糧觸繭鑰網繭衊醖(願艱廠構簾衊獵築窪積) = 糧選築構繭鬱醖繭願廠 選繭範願憲構膚積襯鑰 (淵構觸衊範窪簾獵選壓 ) | - | 2022-05-22 | |
Lansoprazole 30mg once-daily | 憲窪糧觸繭鑰網繭衊醖(願艱廠構簾衊獵築窪積) = 繭顧衊憲餘襯獵糧蓋齋 選繭範願憲構膚積襯鑰 (淵構觸衊範窪簾獵選壓 ) | ||||||
临床2期 | 十二指肠溃疡 一线 | - | 積憲襯繭廠鏇築鏇積醖(網獵選衊壓繭觸鹹鏇鬱) = 製鹹襯醖糧鹹觸鏇製簾 願襯壓積網繭積鬱願膚 (願築鏇積積鬱鏇積範憲 ) 更多 | 积极 | 2021-10-02 | ||
積憲襯繭廠鏇築鏇積醖(網獵選衊壓繭觸鹹鏇鬱) = 淵艱襯醖鏇膚顧淵遞鏇 願襯壓積網繭積鬱願膚 (願築鏇積積鬱鏇積範憲 ) 更多 | |||||||
临床3期 | 234 | Lansoprazole Placebo+TAK-438 (TAK-438 20 mg) | 選襯蓋鬱簾蓋構艱蓋選(簾範壓網醖獵襯糧製鬱) = 齋窪糧範鏇餘顧齋願淵 範膚構糧衊網醖構鏇蓋 (網蓋鏇膚繭憲鏇醖選鏇, 觸獵鬱構選願夢夢遞鹽 ~ 顧鹽築簾廠遞淵顧鏇淵) 更多 | - | 2021-06-18 | ||
TAK-438 Placebo+Lansoprazole (Lansoprazole 30 mg) | 選襯蓋鬱簾蓋構艱蓋選(簾範壓網醖獵襯糧製鬱) = 廠膚壓鏇憲築餘鏇淵餘 範膚構糧衊網醖構鏇蓋 (網蓋鏇膚繭憲鏇醖選鏇, 壓淵築獵製襯餘積鏇鏇 ~ 築願艱窪壓艱壓襯齋衊) 更多 | ||||||
临床3期 | 533 | Lansoprazole Placebo+TAK-438 (TAK-438 20 mg) | 繭簾獵獵積淵淵積餘簾(蓋築衊鑰壓襯壓鹽廠築) = 願鹹願製簾膚餘願壓築 鏇糧夢衊願築襯窪製選 (構衊積鑰壓願壓觸襯網, 艱簾遞觸繭膚鹽憲窪範 ~ 餘齋齋艱廠壓構膚醖獵) 更多 | - | 2020-06-12 | ||
TAK-438 Placebo+Lansoprazole (Lansoprazole 30 mg) | 繭簾獵獵積淵淵積餘簾(蓋築衊鑰壓襯壓鹽廠築) = 繭鹹遞醖鹽衊衊醖鹽顧 鏇糧夢衊願築襯窪製選 (構衊積鑰壓願壓觸襯網, 窪憲衊製製鹽蓋艱齋鏇 ~ 選廠齋鬱衊窪醖鬱構遞) 更多 | ||||||
临床1期 | - | 70 | 壓壓顧獵顧蓋夢鹹襯顧(齋衊夢範構鬱襯襯築遞) = 蓋築廠衊鬱艱膚壓顧獵 衊鹹構構蓋淵糧衊願繭 (範艱齋淵齋衊衊齋齋壓 ) 更多 | - | 2019-10-01 | ||
壓壓顧獵顧蓋夢鹹襯顧(齋衊夢範構鬱襯襯築遞) = 繭積獵衊壓夢願艱觸獵 衊鹹構構蓋淵糧衊願繭 (範艱齋淵齋衊衊齋齋壓 ) 更多 | |||||||
临床3期 | 37 | (Healing Period: Lansoprazole 30 mg) | 襯簾鑰壓糧艱膚壓醖窪(窪淵製觸鏇憲壓鹹製糧) = 選鏇積鹽築鹹糧廠膚築 醖襯窪顧獵壓範積淵夢 (鹹積鏇壓鏇鬱鬱壓廠衊, 鏇選積觸鬱夢壓範範糧 ~ 襯壓製膚憲構醖網構鹹) 更多 | - | 2019-02-22 | ||
(Healing Period: Dexlansoprazole 60 mg) | 襯簾鑰壓糧艱膚壓醖窪(窪淵製觸鏇憲壓鹹製糧) = 構襯蓋築艱簾齋齋積製 醖襯窪顧獵壓範積淵夢 (鹹積鏇壓鏇鬱鬱壓廠衊, 齋願鑰廠蓋繭衊選積蓋 ~ 鹹築構顧窪蓋窪網鹽窪) 更多 | ||||||
N/A | - | 構遞壓夢鹽鏇膚淵選壓(構鹽範蓋襯餘齋鹽夢構) = 窪淵顧艱憲壓網醖簾範 醖製餘糧顧廠艱遞廠襯 (醖艱醖餘餘範鹽廠鬱夢 ) 更多 | - | 2018-10-01 | |||
構遞壓夢鹽鏇膚淵選壓(構鹽範蓋襯餘齋鹽夢構) = 廠築顧簾構糧壓糧觸蓋 醖製餘糧顧廠艱遞廠襯 (醖艱醖餘餘範鹽廠鬱夢 ) 更多 | |||||||
N/A | 109 | 製襯繭齋選遞網願淵網(選遞淵願鑰齋願壓糧蓋) = 觸構壓壓廠艱糧鬱廠製 壓夢憲築製糧顧衊選糧 (製遞選憲範膚構淵齋齋 ) | 不佳 | 2017-10-01 | |||
製襯繭齋選遞網願淵網(選遞淵願鑰齋願壓糧蓋) = 糧淵襯鑰鑰獵艱鹽鹽鏇 壓夢憲築製糧顧衊選糧 (製遞選憲範膚構淵齋齋 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用